AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2017
Sep 26, 2017
65314_rns_2017-09-26_9c7d5043-710d-4a7a-a2a8-47b93f60ea54.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [222 x 64] intentionally omitted <==
ASX Release
Settlement actions completed with Prime and Manukan; Crescendas debt paid
Sydney, 27 September 2017
Memphasys (ASX: MEM) reports that the following settlement actions have been completed with PrIME Biologics Private Limited (“ Prime ”) and Pulau Manukan Ventures Labuan Ltd (“ Manukan ”) in accordance with the Settlement Agreement signed between the parties on 24 July 2017. ASX announcements related to the Settlement Agreement were made on 27 and 28 July 2017:
-
Manukan now has full rights and ownership over the Preference B Shares in Prime formerly owned by Memphasys.
-
Memphasys is clear of the SG$4.8m debt.
In addition, the $250,000 debt plus interest has been fully repaid to Crescendas Projects Pte Ltd. Details of the loan to the Company were outlined in an ASX announcement on 2 March 2017.
For further information please contact:
Alison Coutts Executive Chairman +61 2 8415 7300 [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Postal Address Contact Details E [email protected] P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556
Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140
DM3\4802566.1